Last updated on June 2017

Biologic Treatment Registry Across Canada

Brief description of study

This registry is a multi-center, prospective, longitudinal, observational program that will gather and analyse data on participants treated with infliximab, golimumab, golimumab Intravenous (I.V) or ustekinumab. Treatment will be prescribed by the physician according to actual clinical practice or standard of care for Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA) , Psoriatic Arthritis (PsA); there will be no randomized assignments to treatment. At baseline and approximately every 6 months thereafter, information will be collected to assess safety, clinical outcomes, quality of life, comorbidities, pharmacoeconomics and treatment regimens among cohorts of participants receiving infliximab, golimumab, golimumab I.V or ustekinumab for the treatment of RA, AxSpA and PsA.

Detailed Study Description

Participants will be selected for this registry using a non-probability sampling method.

Clinical Study Identifier: NCT00741793

Contact Investigators or Research Sites near you

Start Over

Institut de Rhumatologie de Montreal

Institut de Rhumatologie de Montreal
Montreal, QC Canada
  Connect »